Korean Circ J.  2019 Dec;49(12):1199-1200. 10.4070/kcj.2019.0301.

Potent P2Y₁₂ Receptor Inhibition in Korean Patients with Acute Myocardial Infarction

• Kim Y
• Johnson TW
• Jeong MH

• KMID: 2464301
• DOI: http://doi.org/10.4070/kcj.2019.0301

Abstract

No abstract available.

MeSH Terms

Humans
Myocardial Infarction*

Figure

• 

  Figure 1 Result of platelet reactivity assessed by the VerifyNow P2Y12 assay from a retrospective analysis of single-center data of Korean patients with acute myocardial infarction. PRU values are presented as mean±standard deviation and median (interquartile range). PRU = P2Y12 reaction unit.

Reference

1. Yun KH, Cho JY, Rhee SJ, Oh SK. Temporal variability of platelet reactivity in patients treated with clopidogrel or ticagrelor. Korean Circ J. 2019; 49:1052–1061.

2. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39:213–260.

3. Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019; 381:1524–1534.

4. Kim Y, Ahn Y, Cho MC, Kim CJ, Kim YJ, Jeong MH. Current status of acute myocardial infarction in Korea. Korean J Intern Med. 2019; 34:1–10.

5. Kang J, Kim HS. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and “Asian Paradox”. Korean Circ J. 2018; 48:537–551.